Development of skin hypopigmentation in a patient with metastatic papillary carcinoma thyroid treated with Sorafenib

BMC Endocrine Disorders

Volumn 13, Issue , 2013, Pages

  Hussain, Syed Z ^a   Asghar, Ali ^a   Ikram, Mubasher ^a   Islam, Najmul ^a  

^a AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Hypopigmentation; Sorafenib; Thyroid Carcinoma

Indexed keywords

IODINE 131; SORAFENIB; THYROGLOBULIN;

ADULT; ARTICLE; ASPIRATION CYTOLOGY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DESQUAMATION; DIARRHEA; DRUG WITHDRAWAL; FINE NEEDLE ASPIRATION BIOPSY; HAIR LOSS; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HYPOPIGMENTATION; LARYNGOSCOPY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; RECOMMENDED DRUG DOSE; THROAT IRRITATION; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR ABLATION; TUMOR RECURRENCE; TUMOR VOLUME; VOICE CHANGE;

EID: 84881183238     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/1472-6823-13-29     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57(1):43-66. 10.3322/canjclin.57.1.43, 17237035.
2. American cancer society Cancer facts and figures 2010 2010, Atlanta: American cancer society, American cancer society.
3. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg 1996, 172(6):692-694. 10.1016/S0002-9610(96)00310-8, 8988680.
4. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988, 67(3):501-508. 10.1210/jcem-67-3-501, 3410936.
5. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003, 197(2):191-197. 10.1016/S1072-7515(03)00332-6, 12892796.
6. Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(Suppl 2):S37-S43. 2673022, 18437172.
7. Tuttle RM, Fleisher M, Francis GL, Robbins RJ. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. J Clin Endocrinol Metab 2002, 87(4):1737-1742. 10.1210/jc.87.4.1737, 11932308.
8. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B. Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009, 60(2):299-305. 10.1016/j.jaad.2008.06.034, 19028406.
9. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard JY, Lathia C, Schwartz B, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006, 24(26):4293-4300. 10.1200/JCO.2005.01.3441, 16908937.
10. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356(2):125-134. 10.1056/NEJMoa060655, 17215530.
11. Schneider TC, Abdulrahman RM, Corssmit EP, Morreau H, Smit JW, Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur J Endocrinol 2012, 167(5):643-650. 10.1530/EJE-12-0405, 22918300.
12. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008, 26(29):4714-4719. 10.1200/JCO.2008.16.3279, 2653134, 18541894.
13. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27(10):1675-1684. 10.1200/JCO.2008.18.2717, 2668972, 19255327.
14. Brose MS, et al. 'Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: the phase III DECISION trial'. ASCO 2013, Abstract 4 MedPage Today, June 04, 2013.
15. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008, 144(7):886-892. 10.1001/archderm.144.7.886, 18645140.
16. Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, Moon KC, Koh JK. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009, 161(5):1045-1051. 10.1111/j.1365-2133.2009.09290.x, 19558553.
17. Bracarda S, Ruggeri EM, Monti M, Merlano M, D'Angelo A, Ferrau F, Cortesi E, Santoro A. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib working group. Crit Rev Oncol Hematol 2012, 82(3):378-386. 10.1016/j.critrevonc.2011.08.005, 21944842.